

- [1] A. James *et al.*, “Fragile X Premutation Tremor / Ataxia Syndrome : Molecular , Clinical , and Neuroimaging Correlates Se,” pp. 869–878, 2003.
- [2] R. J. Hagerman *et al.*, “Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation,” *Am.J.Hum.Genet.*, vol. 74, no. 0002-9297 (Print), pp. 1051–1056, 2004.
- [3] P. J. Hagerman and R. J. Hagerman, “Fragile X-associated tremor/ataxia syndrome,” *Ann. N. Y. Acad. Sci.*, vol. 1338, no. 1, pp. 58–70, 2015.
- [4] F. Tassone *et al.*, “FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States,” *Genome Med.*, vol. 4, no. 12, p. 100, 2012.
- [5] J. Hunter, O. Rivero-Arias, A. Angelov, E. Kim, I. Fotheringham, and J. Leal, “Epidemiology of fragile X syndrome: A systematic review and meta-analysis,” *Am. J. Med. Genet. Part A*, vol. 164, no. 7, pp. 1648–1658, 2014.
- [6] P. C. Population *et al.*, “Penetrance of the Fragile X – Associated Tremor / Ataxia Syndrome in a,” vol. 291, no. 4, 2015.
- [7] C. M. Greco *et al.*, “Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS),” *Brain*, vol. 129, no. 1, pp. 243–255, 2006.
- [8] C. M. Greco *et al.*, “Neuronal intranuclear inclusions in a new cerebellar tremor / ataxia syndrome among fragile X carriers,” pp. 1760–1771, 2002.
- [9] R. A. M. Buijsen *et al.*, “FMRpolyG-positive inclusions in CNS and non-CNS organs of a fragile X premutation carrier with fragile X-associated tremor / ataxia syndrome,” pp. 1–5, 2014.
- [10] G. Hoem *et al.*, “CGG-repeat length threshold for FMR1 RNA pathogenesis in a cellular model for FXTAS,” vol. 20, no. 11, pp. 2161–2170, 2011.
- [11] S. Y. Fxtas, P. J. Hagerman, and R. J. Hagerman, “F x-a t / a s (fxtas),” vol. 30, no. May 2003, pp. 25–30, 2004.
- [12] C. T. Ashley, K. D. Wilkinson, D. Reines, and S. T. Warren, “FMR1 protein: conserved RNP family domains and selective RNA binding,” *Science*, vol. 262, no. 5133, pp. 563–566, 1993.
- [13] L. N. Smith *et al.*, “Fragile X Mental Retardation Protein Regulates Synaptic and Behavioral Plasticity to Repeated Cocaine Administration,” *Neuron*, vol. 82, no. 3, pp. 645–658, 2014.
- [14] D. L. Nelson, H. T. Orr, and S. T. Warren, “The unstable repeats-Three evolving faces of neurological disease,” *Neuron*, vol. 77, no. 5, pp. 825–843, 2013.
- [15] R. J. Hagerman, D. Protic, and A. Rajaratnam, “Fragile X-Associated Neuropsychiatric Disorders ( FXAND ),” vol. 9, no. November, pp. 1–9, 2018.
- [16] A. Pixxuti *et al.*, “Identification of a Gene ( HIM ? -1 ) Containing a CGG Repeat Coincident with a Breakpoint Cluster Region,” vol. 65, pp. 905–914, 1991.
- [17] I. Fernandez-Carvajal, B. L. Posadas, R. Pan, C. Raske, P. J. Hagerman, and F. Tassone, “Expansion of an FMR1 grey-zone allele to a full mutation in two generations,” *J. Mol. Diagnostics*, vol. 11, no. 4, pp. 306–310, 2009.
- [18] D. Z. Loesch, Q. M. Bui, R. M. Huggins, R. J. Mitchell, R. J. Hagerman, and F. Tassone, “Transcript levels of the intermediate size or grey zone fragile X mental retardation 1 alleles are raised, and correlate with the number of CGG repeats,” *J. Med. Genet.*, vol. 44, no. 3, pp. 200–204, 2007.
- [19] S. S. Chong, “Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders,” no. Id, pp. 1–23, 2016.
- [20] C. Sellier and N. Charlet-berguerand, “FXTAS : Size does matter ! FXTAS : Size does matter !,” vol. 4101, no. February, pp. 20–21, 2016.
- [21] I. Oberlé *et al.*, “Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome,” *Science (80- )*, vol. 252, no. 5009, pp. 1097–1102, 1991.
- [22] J. S. Sutcliffe *et al.*, “DNA methylation represses FMR-1 transcription in fragile x syndrome,” *Hum. Mol. Genet.*, vol. 1, no. 6, pp. 397–400, 1992.
- [23] C. Verheij *et al.*, “Characterization and localization of the FMR-1 gene product,” *Nature*, vol. 363, no. 12, pp. 722–724, 1993.
- [24] M. M. Seltzer, M. W. Baker, J. Hong, M. Maenner, J. Greenberg, and D. Mandel, “Prevalence of CGG Expansions of the FMR1 Gene in a US Population-Based Sample,” no. May, 2012.
- [25] J. Hunter, O. Rivero-Arias, A. Angelov, E. Kim, I. Fotheringham, and J. Leal, “Epidemiology of fragile X syndrome: A systematic review and meta-analysis,” *Am. J. Med. Genet. Part A*, vol. 164, no. 7, pp. 1648–1658, 2014.

- [26] M. J. Maenner *et al.*, “FMR1 CGG expansions: Prevalence and sex ratios,” *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.*, vol. 162, no. 5, pp. 466–473, 2013.
- [27] W. J. Kleijer, M. L. T. van der Sterre, V. H. Garritsen, A. Raams, and N. G. J. Jaspers, “Evolution of prenatal detection of neural tube defects in the pregnant population of the city of Barcelona from 1992 to 2006,” *Prenat. Diagn.*, vol. 31, no. 10, pp. 1184–1188, 2011.
- [28] W. Saldarriaga *et al.*, “Genetic cluster of fragile X syndrome in a Colombian district,” *J. Hum. Genet.*, vol. 63, no. 4, pp. 509–516, Apr. 2018.
- [29] S. Otsuka *et al.*, “Fragile X carrier screening and FMR1 allele distribution in the Japanese population,” *Brain Dev.*, vol. 32, no. 2, pp. 110–114, 2010.
- [30] S. Han, Y. Heo, Y. Yang, Y. Kim, H. Cho, and K. Lee, “Prenatal Population Screening for Fragile X Carrier and the Prevalence of Premutation Carriers in Korea,” vol. 9, no. 2, pp. 73–77, 2012.
- [31] C. C. Tzeng *et al.*, “Prevalence of the FMR1 mutation in Taiwan assessed by large-scale screening of newborn boys and analysis of DXS548-FRAXAC1 haplotype,” *Am. J. Med. Genet.*, vol. 133 A, no. 1, pp. 37–43, 2005.
- [32] R. Pessa *et al.*, “Screening for fragile X syndrome in women of reproductive age,” *Prenat. Diagn.*, vol. 20, no. 8, pp. 611–614, 2000.
- [33] H. Toledano-Alhadeff *et al.*, “Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel,” *Am. J. Hum. Genet.*, vol. 69, no. 2, pp. 351–360, 2001.
- [34] M. Faruq *et al.*, “Parkinsonism and Related Disorders Identification of FXTAS presenting with SCA 12 like phenotype in India,” *Park. Relat. Disord.*, vol. 20, no. 10, pp. 1089–1093, 2014.
- [35] G. M. Espinal, S. Hulsizer, P. J. Hagerman, and I. N. Pessah, “Calcium dysregulation and Cdk5-ATM pathway involved in a mouse model of fragile X-associated tremor / ataxia syndrome,” vol. 26, no. 14, pp. 2649–2666, 2017.
- [36] P. K. Todd *et al.*, “CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome,” *Neuron*, vol. 78, no. 3, pp. 440–455, 2013.
- [37] O. A. Sofola *et al.*, “Suppress Fragile X CGG Premutation Repeat-Induced Neurodegeneration in a Drosophila Model of FXTAS,” pp. 565–571, 2007.
- [38] C. Sellier *et al.*, “Article Sequestration of DROSHA and DGCR8 by Expanded CGG RNA Repeats Alters MicroRNA Processing in Fragile X-Associated Tremor / Ataxia Syndrome Identification of Proteins Associated with Expanded,” *CellReports*, vol. 3, no. 3, pp. 869–880, 2013.
- [39] T. Kolbe *et al.*, “Article mtDNA Segregation in Heteroplasmic Tissues Is Common In Vivo and Modulated by Haplotype Differences and Developmental Stage,” pp. 2031–2041, 2014.
- [40] P. Jin *et al.*, “Article Pur a Binds to rCGG Repeats and Modulates Repeat-Mediated Neurodegeneration in a Drosophila Model of Fragile X Tremor / Ataxia Syndrome,” pp. 556–564, 2007.
- [41] C. K. Iwahashi *et al.*, “Protein composition of the intranuclear inclusions of FXTAS,” pp. 256–271, 2006.
- [42] C. Sellier *et al.*, “Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients,” *EMBO J.*, vol. 29, no. 7, pp. 1248–1261, 2010.
- [43] P. Hagerman, “Fragile X-associated tremor/ataxia syndrome (FXTAS): Pathology and mechanisms,” *Acta Neuropathol.*, vol. 126, no. 1, pp. 1–19, 2013.
- [44] A. Qurashi, W. Li, J. Zhou, J. Peng, and P. Jin, “Nuclear Accumulation of Stress Response mRNAs Contributes to the Neurodegeneration Caused by Fragile X Premutation rCGG Repeats,” vol. 7, no. 6, 2011.
- [45] C. Sellier *et al.*, “Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic and May Contribute to Fragile X Tremor Ataxia Syndrome Article Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic and May Contribute to Fragile X Tremor Ataxia Syndrome,” pp. 331–347, 2017.
- [46] D. Gohel *et al.*, “FMRpolyG alters mitochondrial transcripts level and respiratory chain complex assembly in Fragile X associated tremor/ataxia syndrome [FXTAS],” *Biochim. Biophys. Acta - Mol. Basis Dis.*, vol. 1865, no. 6, 2019.
- [47] K. Reddy *et al.*, “Determinants of R-loop formation at convergent bidirectionally transcribed trinucleotide repeats,” vol. 39, no. 5, pp. 1749–1762, 2011.
- [48] H. F. M. R. C. Region, E. W. Loomis, and L. A. Sanz, “Transcription-Associated R-Loop Formation across the,” vol. 10, no. 4, 2014.
- [49] M. Groh, M. M. P. Lufino, R. Wade-Martins, and N. Gromak, “R-loops Associated with Triplet Repeat Expansions Promote Gene Silencing in Friedreich Ataxia and Fragile X Syndrome,” vol. 10, no. 5, 2014.
- [50] D. Motti, J. L. Bixby, and V. P. Lemmon, “MicroRNAs and neuronal development,” *Semin. Fetal Neonatal Med.*, vol. 17, no. 6, pp. 347–352, 2012.
- [51] A. Schaefer *et al.*, “Cerebellar neurodegeneration in the absence of microRNAs,” *J. Exp. Med.*, vol. 204, no. 7, pp. 1553–1558, 2007.

- [52] T. H. Davis *et al.*, “Conditional loss of dicer disrupts cellular and tissue morphogenesis in the cortex and hippocampus,” *J. Neurosci.*, vol. 28, no. 17, pp. 4322–4330, 2008.
- [53] Maiti and Bidinger, “濟無No Title No Title,” *J. Chem. Inf. Model.*, vol. 53, no. 9, pp. 1689–1699, 1981.
- [54] C. Eitan and E. Hornstein, “Vulnerability of microRNA biogenesis in FTD–ALS,” *Brain Res.*, vol. 1647, pp. 105–111, 2016.
- [55] D. P. Bartel, R. Lee, and R. Feinbaum, “MicroRNAs : Genomics , Biogenesis , Mechanism , and Function Genomics : The miRNA Genes,” vol. 116, pp. 281–297, 2004.
- [56] R. I. Gregory, T. P. Chendrimada, and R. Shiekhattar, “MicroRNA Biogenesis,” vol. 342.
- [57] M. Ha and V. N. Kim, “Regulation of microRNA biogenesis,” *Nat. Rev. Mol. Cell Biol.*, vol. 15, no. 8, pp. 509–524, 2014.
- [58] Y. Lee *et al.*, “The nuclear RNase III Drosha initiates microRNA processing,” vol. 425, no. September, pp. 1–5, 2003.
- [59] H. Tan, M. Poidevin, H. Li, D. Chen, and P. Jin, “MicroRNA-277 Modulates the Neurodegeneration Caused by Fragile X Premutation rCGG Repeats,” vol. 8, no. 5, 2012.
- [60] M. Trabucchi, “Subcellular Heterogeneity of the microRNA Machinery,” *Trends Genet.*, vol. 35, no. 1, pp. 15–28, 2019.
- [61] B. Barman and S. N. Bhattacharyya, “mRNA targeting to endoplasmic reticulum precedes ago protein interaction and MicroRNA (miRNA)-mediated translation repression in mammalian cells,” *J. Biol. Chem.*, vol. 290, no. 41, pp. 24650–24656, 2015.
- [62] S. Li *et al.*, “Biogenesis of phased siRNAs on membrane-bound polysomes in Arabidopsis,” *Elife*, vol. 5, pp. 1–24, 2016.
- [63] S. Li *et al.*, “MicroRNAs inhibit the translation of target mRNAs on the endoplasmic reticulum in arabidopsis,” *Cell*, vol. 153, no. 3, pp. 562–574, 2013.
- [64] A. N. A. Eulalio, F. Triteschler, and E. Izaurralde, “The GW182 protein family in animal cells : New insights into domains required for miRNA-mediated gene silencing,” pp. 1433–1442, 2009.
- [65] L. Sripada, D. Tomar, P. Prajapati, R. Singh, and A. K. Singh, “Systematic Analysis of Small RNAs Associated with Human Mitochondria by Deep Sequencing : Detailed Analysis of Mitochondrial Associated miRNA,” vol. 7, no. 9, 2012.
- [66] S. Das *et al.*, “Nuclear miRNA Regulates the Mitochondrial Genome in the Heart,” pp. 1596–1603, 2012.
- [67] G. Wang *et al.*, “PNPASE regulates RNA import into mitochondria,” *Cell*, vol. 142, no. 3, pp. 456–467, 2010.
- [68] A. K. L. Leung, “The Whereabouts of microRNA Actions: Cytoplasm and Beyond,” *Trends Cell Biol.*, vol. 25, no. 10, pp. 601–610, 2015.
- [69] L. Santangelo *et al.*, “The RNA-Binding Protein SYNCRIP Is a Component of the Hepatocyte Exosomal Machinery Controlling MicroRNA Sorting Article The RNA-Binding Protein SYNCRIP Is a Component of the Hepatocyte Exosomal Machinery Controlling MicroRNA Sorting,” *CellReports*, vol. 17, no. 3, pp. 799–808, 2016.
- [70] S. Pitchiaya *et al.*, “Resolving Subcellular miRNA Trafficking and Turnover at Single-Molecule Resolution Article Resolving Subcellular miRNA Trafficking and Turnover at Single-Molecule Resolution,” *CellReports*, vol. 19, no. 3, pp. 630–642, 2017.
- [71] B. T. Kren, P. Y. P. Wong, A. Sarver, X. Zhang, Y. Zeng, and C. J. Steer, “microRNAs identified in highly purified liver-derived mitochondria may play a role in apoptosis,” *RNA Biol.*, vol. 6, no. 1, pp. 65–72, 2009.
- [72] Z. Bian *et al.*, “Identification of mouse liver mitochondria-associated miRNAs and their potential biological functions,” *Cell Res.*, vol. 20, no. 9, pp. 1076–1078, 2010.
- [73] E. Barrey, G. Saint-auret, B. Bonnamy, D. Damas, and O. Boyer, “Pre-microRNA and Mature microRNA in Human Mitochondria,” vol. 6, no. 5, 2011.
- [74] T. R. Mercer *et al.*, “Resource The Human Mitochondrial Transcriptome,” *Cell*, vol. 146, no. 4, pp. 645–658, 2011.
- [75] X. Zhang *et al.*, “MicroRNA Directly Enhances Mitochondrial Translation during Muscle Differentiation,” *Cell*, vol. 158, no. 3, pp. 607–619, 2014.
- [76] J. Nunnari and A. Suomalainen, “Review Mitochondria : In Sickness and in Health,” *Cell*, vol. 148, no. 6, pp. 1145–1159, 2012.
- [77] I. Madrigal, G. Garrabou, and M. Milà, “Impaired Mitochondrial Function and Dynamics in the Pathogenesis of FXTAS,” pp. 6896–6902, 2017.
- [78] C. Giulivi, E. Napoli, F. Tassone, J. Halmi, and R. Hagerman, “Plasma metabolic profile delineates roles for neurodegeneration , pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation,” pp. 3871–3888, 2016.

- [79] V. Nobile *et al.*, “Altered mitochondrial function in cells carrying a premutation or unmethylated full mutation of the FMR1 gene,” *Hum. Genet.*, vol. 139, no. 2, pp. 227–245, 2020.
- [80] E. Napoli *et al.*, “Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome,” *Hum. Mol. Genet.*, vol. 20, no. 15, pp. 3079–3092, 2011.
- [81] E. Berry-kraavis *et al.*, “Fragile X-Associated Tremor / Ataxia Syndrome : Clinical Features , Genetics , and Testing Guidelines,” vol. 22, no. 14, pp. 2018–2030, 2018.
- [82] T. Botta-Orfila, G. G. Tartaglia, and A. Michalon, “Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development,” *Cerebellum*, vol. 15, no. 5, pp. 599–610, 2016.
- [83] A. M. Cabal-Herrera, N. Tassanakijpanich, M. J. Salcedo-Arellano, and R. J. Hagerman, “Fragile X-associated tremor/ataxia syndrome (FXTAS): Pathophysiology and clinical implications,” *Int. J. Mol. Sci.*, vol. 21, no. 12, pp. 1–23, 2020.
- [84] R. J. Hagerman *et al.*, “Intention tremor , parkinsonism , and generalized brain atrophy in male,” 2001.
- [85] M. J. Salcedo-Arellano, B. Dufour, Y. McLennan, V. Martinez-Cerdeno, and R. Hagerman, “Fragile X syndrome and associated disorders: Clinical aspects and pathology,” *Neurobiol. Dis.*, vol. 136, no. January, p. 104740, 2020.
- [86] C. Badenas, J. Kulisevsky, and B. Gomez, “Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families,” pp. 1359–1362, 2009.
- [87] “FXTAS : Size does matter !,” vol. 13, no. 16, p. 23602499, 2014.
- [88] J. L. Juncos *et al.*, “New clinical findings in the fragile X-associated tremor ataxia syndrome ( FXTAS ),” pp. 123–135, 2011.
- [89] D. A. Hall *et al.*, “Update on the Clinical, Radiographic, and Neurobehavioral Manifestations in FXTAS and FMR1 Premutation Carriers,” *Cerebellum*, vol. 15, no. 5, pp. 578–586, 2016.
- [90] E. Napoli *et al.*, “Warburg effect linked to cognitive-executive deficits in FMR1 premutation,” *FASEB J.*, vol. 30, no. 10, pp. 3334–3351, 2016.
- [91] J. Cogswell *et al.*, “Psychiatric Phenotype of the Fragile X–Associated Tremor/Ataxia Syndrome (FXTAS) in Males: Newly Described Fronto-Subcortical Dementia,” no. January, pp. 87–94, 2006.
- [92] M. Gokden, J. T. Al-Hinti, and S. I. Harik, “Peripheral nervous system pathology in fragile X tremor/ataxia syndrome (FXTAS),” *Neuropathology*, vol. 29, no. 3, pp. 280–284, 2009.
- [93] A. A. Hamlin *et al.*, “Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS),” *Am. J. Med. Genet. Part A*, vol. 158 A, no. 6, pp. 1304–1309, 2012.
- [94] A. Hamlin, Y. Liu, D. V. Nguyen, F. Tassone, L. Zhang, and R. J. Hagerman, “Sleep apnea in fragile X premutation carriers with and without FXTAS,” *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.*, vol. 156, no. 8, pp. 923–928, 2011.
- [95] J. Au *et al.*, “Prevalence and risk of migraine headaches in adult fragile X premutation carriers,” *Clin. Genet.*, vol. 84, no. 6, pp. 546–551, 2013.
- [96] A. C. Wheeler *et al.*, “Associated features in females with an FMR1 premutation,” *J. Neurodev. Disord.*, vol. 6, no. 1, pp. 1–14, 2014.
- [97] J. L. Juncos *et al.*, “Olfactory dysfunction in fragile X tremor ataxia syndrome,” *Mov. Disord.*, vol. 27, no. 12, pp. 1556–1559, 2012.
- [98] S. M. Summers *et al.*, “Fatigue and body mass index in the Fragile X premutation carrier,” *Fatigue Biomed. Heal. Behav.*, vol. 2, no. 2, pp. 64–72, 2014.
- [99] L. P. Kok and S. T. Lee, “Psychiatric disorders associated with burns.,” *Ann. Acad. Med. Singapore*, vol. 21, no. 5, pp. 672–676, 1992.
- [100] M. A. Leehey, W. Legg, F. Tassone, and R. Hagerman, “Concise report Fibromyalgia in fragile X mental retardation 1 gene premutation carriers,” no. September, pp. 2233–2236, 2011.
- [101] T. I. Winarni *et al.*, “Immune-mediated disorders among women carriers of fragile X premutation alleles,” *Am. J. Med. Genet. Part A*, vol. 158 A, no. 10, pp. 2473–2481, 2012.
- [102] S. M. Coffey *et al.*, “Expanded Clinical Phenotype of Women With the FMR1 Premutation,” vol. 1016, pp. 1009–1016, 2008.
- [103] J. A. Brunberg *et al.*, “Fragile X Premutation Carriers : Characteristic MR Imaging Findings of Adult Male Patients with Progressive Cerebellar and Cognitive Dysfunction,” no. December, pp. 1757–1766, 2002.
- [104] D. Z. Loesch *et al.*, “White matter changes in basis pontis in small expansion FMR1 allele carriers with parkinsonism,” *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.*, vol. 156, no. 4, pp. 502–506, 2011.
- [105] E. Storey and P. Billimoria, “Increased T2 signal in the middle cerebellar peduncles on MRI is not specific for fragile X p4remutation syndrome,” *J. Clin. Neurosci.*, vol. 12, no. 1, pp. 42–43, 2005.

- [106] K. Okamoto, S. Tokiguchi, T. Furusawa, and K. Ishikawa, "MR Features of Diseases Involving Bilateral Middle Cerebellar Peduncles," no. December, pp. 1946–1954, 2003.
- [107] S. Cohen *et al.*, "Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome," *Neurology*, vol. 67, no. 8, pp. 1426–1431, 2006.
- [108] C. J. Moore *et al.*, "The effect of pre-mutation of X chromosome CGG trinucleotide repeats on brain anatomy," *Brain*, vol. 127, no. 12, pp. 2672–2681, 2004.
- [109] S. L. Nolin *et al.*, "Fragile X AGG analysis provides new risk predictions for 45-69 repeat alleles," *Am. J. Med. Genet. Part A*, vol. 161, no. 4, pp. 771–778, 2013.
- [110] S. L. Nolin *et al.*, "Expansions and contractions of the FMR1 CGG repeat in 5,508 transmissions of normal, intermediate, and premutation alleles," *Am. J. Med. Genet. Part A*, vol. 179, no. 7, pp. 1148–1156, 2019.
- [111] K. Snow, L. K. Doud, R. Hagerman, R. G. Pergolizzi, S. H. Erster, and S. N. Thibodeau, "Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population," *Am. J. Hum. Genet.*, vol. 53, no. 6, pp. 1217–1228, 1993.
- [112] Y. Fu *et al.*, "Variation of the CGG Repeat at the Fragile X Site Results in Genetic Instability : Resolution of the Sherman Paradox," vol. 67, pp. 1047–1056, 1991.
- [113] N. Zhong, W. Ju, J. Pietrofesa, D. Wang, C. Dobkin, and W. T. Brown, "Fragile X 'Gray Zone' Alleles: AGG Patterns, Expansion Risks, and Associated Haplotypes," *Am. J. Med. Genet. - Semin. Med. Genet.*, vol. 64, no. 2, pp. 261–265, 1996.
- [114] E. E. Eichler *et al.*, "Length of uninterrupted CGG repeats determines instability in the FMR1 gene," *Nat. Genet.*, vol. 8, no. 1, pp. 88–94, 1994.
- [115] M. Napierala, D. Michalowski, M. de Mezer, and W. J. Krzyzosiak, "Facile FMR1 mRNA structure regulation by interruptions in CGG repeats," *Nucleic Acids Res.*, vol. 33, no. 2, pp. 451–463, 2005.
- [116] A. G. Hadd *et al.*, "A methylation PCR method determines FMR1 activation ratios and differentiates premutation allele mosaicism in carrier siblings," *Clin. Epigenetics*, vol. 8, no. 1, pp. 1–9, 2016.
- [117] J. R. Brouwer, *The Molecular basis of FXTAS*. 2008.
- [118] A. Entezam *et al.*, "Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model," vol. 395, pp. 125–134, 2007.
- [119] R. Lozano, A. Azarang, T. Wilaisakditipakorn, and R. J. Hagerman, "Fragile X syndrome: A review of clinical management," *Intractable Rare Dis. Res.*, vol. 5, no. 3, pp. 145–157, 2016.
- [120] D. Garcia-arocena and P. J. Hagerman, "Advances in understanding the molecular basis of FXTAS," vol. 19, no. 1, pp. 83–89, 2010.
- [121] F. Tassone *et al.*, "Elevated FMR1 mRNA in premutation carriers is due to increased transcription," pp. 555–562, 2007.
- [122] D. G. Arocena *et al.*, "Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells," *Hum. Mol. Genet.*, vol. 14, no. 23, pp. 3661–3671, 2005.
- [123] R. A. M. Buijsen *et al.*, "Presence of inclusions positive for polyglycine containing protein, FMRpolyG, indicates that repeat-associated non-AUG translation plays a role in fragile X-associated primary ovarian insufficiency," *Hum. Reprod.*, vol. 31, no. 1, pp. 158–168, 2016.
- [124] D. Garcia-arocena *et al.*, "Fibroblast phenotype in male carriers of FMR1 premutation alleles," vol. 19, no. 2, pp. 299–312, 2010.
- [125] P. D. Ladd *et al.*, "An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals," *Hum. Mol. Genet.*, vol. 16, no. 24, pp. 3174–3187, 2007.
- [126] C. Ross-Inta *et al.*, "Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome," *Biochem. J.*, vol. 429, no. 3, pp. 545–552, 2010.
- [127] S. N. Haify, T. Botta-Orfila, R. K. Hukema, and G. G. Tartaglia, "In silico, in vitro, and in vivo Approaches to Identify Molecular Players in Fragile X Tremor and Ataxia Syndrome," *Front. Mol. Biosci.*, vol. 7, no. March, pp. 1–12, 2020.
- [128] M. Costa-Mattioli, W. S. Sossin, E. Klann, and N. Sonenberg, "Translational Control of Long-Lasting Synaptic Plasticity and Memory," *Neuron*, vol. 61, no. 1, pp. 10–26, 2009.
- [129] R. Willemsen, B. A. Oostra, G. J. Bassell, and J. Dichtenberg, "The Fragile X Syndrome: From Molecular Genetics to Neurobiology," *Ment. Retard. Dev. Disabil. Res. Rev.*, vol. 10, no. 1, pp. 60–67, 2004.
- [130] J. C. Darnell, K. B. Jensen, P. Jin, V. Brown, S. T. Warren, and R. B. Darnell, "Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function," *Cell*, vol. 107, no. 4, pp. 489–499, 2001.
- [131] J. C. Darnell *et al.*, "Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes," *Genes Dev.*, vol. 19, no. 8, pp. 903–918, 2005.

- [132] V. Brown *et al.*, “Microarray Identification of FMRP-Associated Brain mRNAs and Altered mRNA Translational Profiles in Fragile X Syndrome,” vol. 107, pp. 477–487, 2001.
- [133] K. Y. Miyashiro *et al.*, “RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice,” *Neuron*, vol. 37, no. 3, pp. 417–431, 2003.
- [134] S. B. Christie, M. R. Akins, J. E. Schwob, and J. R. Fallon, “The FXG : A Presynaptic Fragile X Granule Expressed in a Subset of Developing Brain Circuits,” vol. 29, no. 5, pp. 1514–1524, 2009.
- [135] M. A. Kiebler and G. J. Bassell, “Neuronal RNA Granules : Movers and Makers,” pp. 685–690, 2006.
- [136] Y. Luo and Z. Na, “P - Bodies: Composition, Properties, and Functions,” 2018.
- [137] L. K. K. Pacey and L. C. Doering, “Developmental Expression of FMRP in the Astrocyte Lineage : Implications for Fragile X Syndrome,” vol. 1609, no. December 2006, pp. 1601–1609, 2007.
- [138] S. Jacobs and L. C. Doering, “Astrocytes Prevent Abnormal Neuronal Development in the Fragile X Mouse,” vol. 30, no. 12, pp. 4508–4514, 2010.
- [139] A. A. Caudy, M. Myers, G. J. Hannon, and S. M. Hammond, “Fragile X-related protein and VIG associate with the RNA interference machinery,” *Genes Dev.*, vol. 16, no. 19, pp. 2491–2496, 2002.
- [140] P. Jin *et al.*, “Biochemical and genetic interaction between the fragile X mental retardation protein 3rd the microRNA pathway,” *Nat. Neurosci.*, vol. 7, no. 2, pp. 113–117, 2004.
- [141] A. Ishizuka, M. C. Siomi, and H. Siomi, “A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins,” *Genes Dev.*, vol. 16, no. 19, pp. 2497–2508, 2002.
- [142] X. L. Xu, Y. Li, F. Wang, and F. B. Gao, “The steady-state level of the nervous-system-specific microRNA-124a is regulated by dFMR1 in Drosophila,” *J. Neurosci.*, vol. 28, no. 46, pp. 11883–11889, 2008.
- [143] P. Jin, R. S. Alisch, and S. T. Warren, “RNA and microRNAs in fragile X mental retardation,” *Nat. Cell Biol.*, vol. 6, no. 11, pp. 1048–1053, 2004.
- [144] A. Cheever and S. Ceman, “Phosphorylation of FMRP inhibits association with Dicer,” vol. 2, pp. 362–366, 2009.
- [145] V. Ambros, “The functions of animal microRNAs,” *Nature*, vol. 431, no. 7006, pp. 350–355, 2004.
- [146] J. Alles *et al.*, “An estimate of the total number of true human miRNAs,” *Nucleic Acids Res.*, vol. 47, no. 7, pp. 3353–3364, 2019.
- [147] J. Winter, S. Jung, S. Keller, R. I. Gregory, and S. Diederichs, “Many roads to maturity : microRNA biogenesis pathways and their regulation,” vol. 11, no. 3, 2009.
- [148] J. Han, Y. Lee, K. H. Yeom, Y. K. Kim, H. Jin, and V. N. Kim, “The Drosha-DGCR8 complex in primary microRNA processing,” *Genes Dev.*, vol. 18, no. 24, pp. 3016–3027, 2004.
- [149] H. Kumar, M. Kumar, R. Kumar, and N. H. Greig, “miRNAs : Key Players in Neurodegenerative Disorders and Epilepsy,” vol. 48, pp. 563–580, 2015.
- [150] F. Tassone, R. J. Hagerman, A. K. Taylor, L. W. Gane, T. E. Godfrey, and P. J. Hagerman, “Elevated Levels of FMR1 mRNA in Carrier Males : A New Mechanism of Involvement in the Fragile-X Syndrome,” pp. 6–15, 2000.
- [151] E. Martí and M. Mil, “MicroRNA expression profiling in blood from fragile X-associated tremor / ataxia syndrome patients,” pp. 595–603, 2013.
- [152] A. Chatterjee, S. Dasgupta, and D. Sidransky, “Mitochondrial Subversion in Cancer,” vol. 4, no. May, pp. 638–655, 2011.
- [153] D. Kjølhede, V. A. Bohr, and T. Stevnsner, “Progress in Neurobiology DNA repair deficiency in neurodegeneration,” vol. 94, pp. 166–200, 2011.
- [154] I. Prizes, “Review Mitochondria : Sovereign of inflammation ?,” pp. 1196–1202, 2011.
- [155] H. A. L. Tuppen, E. L. Blakely, D. M. Turnbull, and R. W. Taylor, “Biochimica et Biophysica Acta Mitochondrial DNA mutations and human disease,” *BBA - Bioenerg.*, vol. 1797, no. 2, pp. 113–128, 2010.
- [156] N. Yu, Y. Zhang, K. Zhang, Y. Xie, X. Lin, and Q. Di, “MELAS and Kearns – Sayre overlap syndrome due to the mtDNA m . A3243G mutation and large-scale mtDNA deletions,” *ENSCI*, vol. 4, pp. 15–18, 2016.
- [157] C. Münscher, T. Rieger, J. Müller-Höcker, and B. Kadenbach, “The point mutation of mitochondrial DNA characteristic for MERRF disease is found also in healthy people of different ages,” *FEBS Lett.*, vol. 317, no. 1–2, pp. 27–30, 1993.
- [158] A. H. V Schapira, “Mitochondrial diseases,” vol. 6736, no. 11, pp. 1–10, 2012.
- [159] Y. Shiau and N. Doug, “Mitochondrial disease : genetics and management,” *J. Neurol.*, 2015.
- [160] L. C. Greaves, A. K. Reeve, R. W. Taylor, and D. M. Turnbull, “Mitochondrial DNA and disease,” pp. 274–286, 2012.
- [161] E. A. Schon and S. Przedborski, “Review Mitochondria : The Next ( Neurode ) Generation,” *Neuron*, vol. 70, no. 6, pp. 1033–1053, 2011.

- [162] G. Rizzo *et al.*, “A case of fragile x premutation tremor/ataxia syndrome with evidence of mitochondrial dysfunction [5],” *Mov. Disord.*, vol. 21, no. 9, pp. 1541–1542, 2006.
- [163] A. Shmueli and M. Oren, “Life, death, and ubiquitin: Taming the mule,” *Cell*, vol. 121, no. 7, pp. 963–965, 2005.
- [164] G. Song and E. Napoli, “Altered Redox Mitochondrial Biology in the Neurodegenerative Disorder Fragile X-Tremor/Ataxia Syndrome: Use of Antioxidants in Precision Medicine,” *Mol. Med.*, vol. 22, no. 1, p. 1, 2016.
- [165] Y. Chen *et al.*, “Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration,” vol. 19, no. 1, pp. 196–208, 2010.
- [166] R. K. Hukema *et al.*, “Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo,” *Cell Cycle*, vol. 13, no. 16, pp. 2600–2608, 2014.
- [167] D. Z. Loesch *et al.*, “Evidence for the toxicity of bidirectional transcripts and mitochondrial dysfunction in blood associated with small CGG expansions in the FMR1 gene in patients with parkinsonism,” *Genet. Med.*, vol. 13, no. 5, pp. 392–399, 2011.
- [168] M. I. Alvarez-mora, “This article is protected by copyright. All rights reserved.”
- [169] R. Hagerman and P. Hagerman, “Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor / ataxia syndrome,” *Lancet Neurol.*, vol. 12, no. 8, pp. 786–798, 2013.
- [170] J. Sawashita, A. Takeda, and S. Okada, “Change of zinc distribution in rat brain with increasing age,” *Dev. Brain Res.*, vol. 102, no. 2, pp. 295–298, 1997.
- [171] M. Picard and B. S. McEwen, “Mitochondria impact brain function and cognition,” *Proc. Natl. Acad. Sci. U. S. A.*, vol. 111, no. 1, pp. 7–8, 2014.
- [172] S. Levi and E. Rovida, “The role of iron in mitochondrial function,” *Biochim. Biophys. Acta - Gen. Subj.*, vol. 1790, no. 7, pp. 629–636, 2009.
- [173] J. Ariza *et al.*, “Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome,” *Brain Res.*, vol. 1598, pp. 88–96, 2015.
- [174] J. Ariza *et al.*, “Iron accumulation and dysregulation in the putamen in fragile X-associated tremor/ataxia syndrome,” *Mov. Disord.*, vol. 32, no. 4, pp. 585–591, 2017.
- [175] J. W. Miller *et al.*, “Recruitment of human muscleblind proteins to ( CUG ) n expansions associated with myotonic dystrophy,” vol. 19, no. 17, pp. 4439–4448, 2000.
- [176] P. J. Hagerman, “nd es Bio sci Do No t D ist r ibu,” no. August, pp. 103–105, 2004.
- [177] F. X. Tremor *et al.*, “An Integrative Study of Protein-RNA Condensates Identifies Scaffolding RNAs and Reveals Players in Article An Integrative Study of Protein-RNA Condensates Identifies Scaffolding RNAs and Reveals Players in Fragile X-Associated Tremor / Ataxia Syndrome,” *CellReports*, vol. 25, no. 12, pp. 3422-3434.e7, 2018.
- [178] B. Bolognesi *et al.*, “A concentration-dependent liquid phase separation can cause toxicity upon increased protein expression,” *Cell Rep.*, vol. 16, no. 1, pp. 222–231, 2016.
- [179] F. Cid-Samper *et al.*, “An Integrative Study of Protein-RNA Condensates Identifies Scaffolding RNAs and Reveals Players in Fragile X-Associated Tremor/Ataxia Syndrome,” *Cell Rep.*, vol. 25, no. 12, pp. 3422-3434.e7, 2018.
- [180] S. Markmiller *et al.*, “in Protein Interactions within Stress Granules Context-Dependent and Disease-Specific Diversity,” pp. 590–604, 2018.
- [181] B. F. Maziuk *et al.*, “RNA binding proteins co-localize with small tau inclusions in tauopathy,” pp. 1–14, 2018.
- [182] Y. Hu, H. Deng, S. Xu, and J. Zhang, “MicroRNAs Regulate Mitochondrial Function in Cerebral Ischemia-Reperfusion Injury,” pp. 24895–24917, 2015.
- [183] P. Prajapati *et al.*, “Systemic Analysis of miRNAs in PD Stress Condition: miR-5701 Modulates Mitochondrial–Lysosomal Cross Talk to Regulate Neuronal Death,” *Mol. Neurobiol.*, pp. 1–13, 2017.
- [184] T. Zu, B. Gibbens, N. S. Doty, M. Gomes-pereira, A. Huguet, and M. D. Stone, “Non-ATG – initiated translation directed by microsatellite expansions,” pp. 1–6, 2010.
- [185] K. M. Green, A. E. Linsalata, and P. K. Todd, “RAN translation — What makes it run ?,” *Brain Res.*, pp. 1–13, 2016.
- [186] J. D. Cleary and L. P. W. Ranum, “ScienceDirect Repeat associated non-ATG ( RAN ) translation : new starts in microsatellite expansion disorders,” *Curr. Opin. Genet. Dev.*, vol. 26, pp. 6–15, 2014.
- [187] P. K. Todd *et al.*, “Article CGG Repeat-Associated Translation Mediates Neurodegeneration in Fragile X Tremor Ataxia Syndrome,” *Neuron*, vol. 78, no. 3, pp. 440–455, 2013.
- [188] M. G. Kearse *et al.*, “CGG Repeat-Associated Non-AUG Translation Utilizes a Cap-Dependent Scanning Mechanism of Initiation to Produce Toxic Proteins Short Article CGG Repeat-Associated Non-AUG

- Translation Utilizes a Cap-Dependent Scanning Mechanism of Initiation to Produce Toxi,” *Mol. Cell*, vol. 62, no. 2, pp. 314–322, 2016.
- [189] S. E. Calvo and V. K. Mootha, “The Mitochondrial Proteome and Human Disease,” 2010.
- [190] D. Gohel, L. Sripada, P. Prajapati, K. Singh, and M. Roy, “BBA - Molecular Basis of Disease FMRpolyG alters mitochondrial transcripts level and respiratory chain complex assembly in Fragile X associated tremor / ataxia syndrome [ FXTAS ],” *BBA - Mol. Basis Dis.*, vol. 1865, no. 6, pp. 1379–1388, 2019.
- [191] G. Korza, M. W. Baker, M. Li, A. Bhattacharyya, E. Barbarese, and J. H. Carson, “CGG Repeats in the 5' UTR of FMR1 RNA Regulate Translation of Other RNAs Localized in the Same RNA Granules,” vol. 1, pp. 1–23, 2016.
- [192] R. Tabet, E. Moutin, J. A. J. Becker, D. Heintz, L. Fouillen, and E. Flatter, “Fragile X Mental Retardation Protein ( FMRP ) controls diacylglycerol kinase activity in neurons,” pp. 3619–3628, 2016.
- [193] E. G. Bechara, M. C. Didiot, M. Melko, L. Davidovic, M. Bensaid, and B. Bardoni, “A Novel Function for Fragile X Mental Retardation Protein in Translational Activation,” vol. 7, no. 1, 2009.
- [194] P. J. Kenny *et al.*, “recognition elements,” vol. 9, no. 5, pp. 1729–1741, 2014.
- [195] F. Tafuri, D. Ronchi, F. Magri, G. P. Comi, and S. Corti, “SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis,” vol. 9, no. August, pp. 1–12, 2015.
- [196] M. Chekulaeva and W. Filipowicz, “Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells,” *Curr. Opin. Cell Biol.*, vol. 21, no. 3, pp. 452–460, 2009.
- [197] L. Sripada *et al.*, “hsa-miR-4485 regulates mitochondrial functions and inhibits the tumorigenicity of breast cancer cells,” *J. Mol. Med.*, vol. 95, no. 6, pp. 641–651, 2017.
- [198] P. M. Borralho, C. M. P. Rodrigues, and C. J. Steer, “microRNAs in Mitochondria : An Unexplored Niche,” pp. 31–51.
- [199] R. Zhou *et al.*, “Mitochondria-related miR-151a-5p reduces cellular ATP production by targeting CYTB in asthenozoospermia,” *Sci. Rep.*, vol. 5, no. November, pp. 1–10, 2015.
- [200] R. W. Carthew and E. J. Sontheimer, “Origins and Mechanisms of miRNAs and siRNAs,” *Cell*, vol. 136, no. 4, pp. 642–655, 2009.
- [201] S. Bandiera, R. Matégot, M. Girard, J. Demongeot, and A. Henrion-caude, “Free Radical Biology and Medicine MitomiRs delineating the intracellular localization of microRNAs at mitochondria,” *Free Radic. Biol. Med.*, vol. 64, pp. 12–19, 2013.
- [202] D. Tomar *et al.*, “TRIM4; A novel mitochondrial interacting RING E3 ligase, sensitizes the cells to hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) induced cell death,” *Free Radic. Biol. Med.*, vol. 89, pp. 1036–1048, 2015.
- [203] S. Filipovic-Sadic *et al.*, “A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome,” *Clin. Chem.*, vol. 56, no. 3, pp. 399–408, 2010.
- [204] F. Tassone, R. Pan, K. Amiri, A. K. Taylor, and P. J. Hagerman, “A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations,” *J. Mol. Diagnostics*, vol. 10, no. 1, pp. 43–49, 2008.
- [205] P. Prajapati, L. Sripada, K. Singh, K. Bhatelia, R. Singh, and R. Singh, “Biochimica et Biophysica Acta TNF- $\alpha$  regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells,” *BBA - Mol. Basis Dis.*, vol. 1852, no. 3, pp. 451–461, 2015.
- [206] S. M. Smith, M. B. Wunder, D. A. Norris, and Y. G. Shellman, “A Simple Protocol for Using a LDH-Based Cytotoxicity Assay to Assess the Effects of Death and Growth Inhibition at the Same Time,” vol. 6, no. 11, 2011.
- [207] P. Jha, X. Wang, and J. Auwerx, “Analysis of Mitochondrial Respiratory ( BN-PAGE ),” vol. 6, no. March, pp. 1–14, 2016.
- [208] M. R. Green and J. Sambrook, “Isolation of High-Molecular-Weight DNA Using Organic Solvents,” pp. 356–360, 2017.
- [209] A. N. Malik, R. Shahni, A. Rodriguez-de-ledesma, A. Laftah, and P. Cunningham, “Biochemical and Biophysical Research Communications Mitochondrial DNA as a non-invasive biomarker: Accurate quantification using real time quantitative PCR without co-amplification of pseudogenes and dilution bias,” *Biochem. Biophys. Res. Commun.*, vol. 412, no. 1, pp. 1–7, 2011.
- [210] K. Singh, L. Sripada, A. Lipatova, M. Roy, and P. Prajapati, “BBA - Molecular Cell Research NLRX1 resides in mitochondrial RNA granules and regulates mitochondrial RNA processing and bioenergetic adaptation,” *BBA - Mol. Cell Res.*, vol. 1865, no. 9, pp. 1260–1276, 2018.
- [211] I. Balcells, S. Cirera, and P. K. Busk, “Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers,” *BMC Biotechnol.*, vol. 11, no. 1, p. 70, 2011.
- [212] G. P. Mcdermott *et al.*, “Multiplexed target detection using DNA- binding dye chemistry in droplet digital

- PCR,” 2013.
- [213] X. Wang and X. Wang, “miRDB : A microRNA target prediction and functional annotation database with a wiki interface miRDB : A microRNA target prediction and functional annotation database with a wiki interface,” pp. 1012–1017, 2008.
- [214] S. Liu, H. Zhou, L. Qu, and J. Yang, “miRNA-ncRNA and protein – RNA interaction networks from large-scale CLIP-Seq data,” no. December, 2013.
- [215] D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources,” no. 2, 2008.
- [216] P. Jin *et al.*, “RNA-Mediated Neurodegeneration Caused by the Fragile X Premutation rCGG Repeats in *Drosophila*,” vol. 39, pp. 739–747, 2003.
- [217] R. K. Hukema *et al.*, “Reversibility of neuropathology and motor deficits in an inducible mouse model for FXTAS,” vol. 24, no. 17, pp. 4948–4957, 2015.
- [218] V. Hashem *et al.*, “Ectopic expression of CGG containing mRNA is neurotoxic in mammals,” vol. 18, no. 13, pp. 2443–2451, 2018.
- [219] F. Tassone, C. Iwahashi, and P. J. Hagerman, “FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS).,” *RNA Biol.*, vol. 1, no. 2, pp. 103–105, 2004.
- [220] R. A. M. Buijsen *et al.*, “FMRpolyG-positive inclusions in CNS and non-CNS organs of a fragile X premutation carrier with fragile X-associated tremor/ataxia syndrome,” *Acta Neuropathol. Commun.*, vol. 2, no. 1, pp. 1–5, 2014.
- [221] E. R. Whittemore, “PEROXIDE-INDUCED CELL DEATH IN PRIMARY NEURONAL CULTURE,” vol. 61, no. 4, 1995.
- [222] J. Li and J. Yuan, “Caspases in apoptosis and beyond,” pp. 6194–6206, 2008.
- [223] S. Elmore, “Apoptosis: A Review of Programmed Cell Death,” *Toxicol. Pathol.*, vol. 35, no. 4, pp. 495–516, 2007.
- [224] R. C. Scaduto and L. W. Grotyohann, “Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives.,” *Biophys. J.*, vol. 76, no. 1 Pt 1, pp. 469–77, 1999.
- [225] E. Lapuente-Brun *et al.*, “Supercomplex assembly determines electron flux in the mitochondrial electron transport chain,” *Science (80-. )*, vol. 340, no. 6140, pp. 1567–1570, 2013.
- [226] R. Acín-Pérez, P. Fernández-Silva, M. L. Peleato, A. Pérez-Martos, and J. A. Enriquez, “Respiratory Active Mitochondrial Supercomplexes,” *Mol. Cell*, vol. 32, no. 4, pp. 529–539, 2008.
- [227] M. L. Genova and G. Lenaz, “Functional role of mitochondrial respiratory supercomplexes,” *Biochim. Biophys. Acta - Bioenerg.*, vol. 1837, no. 4, pp. 427–443, 2014.
- [228] J. Montoya, M. J. López-Pérez, and E. Ruiz-Pesini, “Mitochondrial DNA transcription and diseases: Past, present and future,” *Biochim. Biophys. Acta - Bioenerg.*, vol. 1757, no. 9–10, pp. 1179–1189, 2006.
- [229] C. Giulivi, E. Napoli, F. Tassone, J. Halmai, and R. Hagerman, “Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation,” *Biochem. J.*, vol. 473, no. 21, pp. 3871–3888, 2016.
- [230] A. Federico, E. Cardaioli, P. Da Pozzo, P. Formichi, G. N. Gallus, and E. Radi, “Journal of the Neurological Sciences Mitochondria , oxidative stress and neurodegeneration,” *J. Neurol. Sci.*, vol. 322, no. 1–2, pp. 254–262, 2012.
- [231] E. S. Kaplan *et al.*, “Early mitochondrial abnormalities in hippocampal neurons cultured from *Fmr1* premutation mouse model,” *J. Neurochem.*, vol. 123, no. 4, pp. 613–621, 2012.
- [232] O. Rackham *et al.*, “Hierarchical RNA Processing Is Required for Mitochondrial Ribosome Assembly,” *Cell Rep.*, vol. 16, no. 7, pp. 1874–1890, 2016.
- [233] H. Antonicka and E. A. Shoubridge, “Mitochondrial RNA Granules Are Centers for Posttranscriptional RNA Processing and Ribosome Biogenesis,” *Cell Rep.*, vol. 10, no. 6, pp. 920–932, 2015.
- [234] Y. Zhang *et al.*, “Article Secreted Monocytic miR-150 Enhances Targeted Endothelial Cell Migration,” pp. 133–144, 2010.
- [235] M. Girard, N. Cagnard, S. Hanein, S. Bandiera, and S. Ru, “Nuclear Outsourcing of RNA Interference Components to Human Mitochondria,” vol. 6, no. 6, 2011.
- [236] P. J. Magalhães, A. L. Andreu, and E. A. Schon, “Evidence for the presence of 5S rRNA in mammalian mitochondria,” *Mol. Biol. Cell*, vol. 9, no. 9, pp. 2375–2382, 1998.
- [237] A. Smirnov, N. Entelis, R. P. Martin, and I. Tarassov, “Biological significance of 5S rRNA import into human mitochondria : role of ribosomal protein MRP-L18,” pp. 1289–1305, 2011.
- [238] L. Feng, “Long noncoding RNA 00460 ( LINC00460 ) promotes glioma progression by negatively regulating miR - 320a,” no. October 2018, pp. 1–8, 2019.

- [239] C. Li, S. Zhang, T. Qiu, Y. Wang, and D. M. Ricketts, "Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a," *Cancer Biol. Ther.*, vol. 00, no. 00, pp. 1–10, 2018.
- [240] E. Miotto, E. Saccenti, L. Lupini, E. Callegari, M. Negrini, and M. Ferracin, "CEBP FOCUS Quantification of Circulating miRNAs by Droplet Digital PCR : Comparison of EvaGreen- and TaqMan-Based Chemistries," vol. 23, no. December, 2014.
- [241] C. M. Hindson *et al.*, "Absolute quantification by droplet digital PCR versus analog real-time PCR," *Nat. Methods*, no. september, pp. 1–6, 2013.
- [242] M. P. Rodrigues, C. J. Steer, M. Á. Mitochondria-associated, Á. Mitoplasm, and Á. Purified, "Mitochondrial MicroRNAs and Their Potential Role in Cell Function," pp. 123–132, 2014.
- [243] L. To and T. H. E. Editor, "Identification of mouse liver mitochondria-associated miRNAs and their potential biological functions," vol. 20, no. 9, pp. 1076–1078, 2010.
- [244] R. F. Berman *et al.*, "Mouse models of the fragile X premutation and fragile X-associated tremor / ataxia syndrome," pp. 1–16, 2014.
- [245] C. Sellier, K. Usdin, C. Pastori, V. J. Peschansky, F. Tassone, and N. Charlet-Berguerand, "The multiple molecular facets of fragile X-associated tremor/ataxia syndrome," *J. Neurodev. Disord.*, vol. 6, no. 1, pp. 1–10, 2014.
- [246] D. L. Shepherd *et al.*, "Division of Exercise Physiology Running Title : PNPase mitochondrial microRNA import," *J. Mol. Cell. Cardiol.*, 2017.
- [247] S. Fan *et al.*, "Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription," pp. 1069–1085, 2019.
- [248] R. Jagannathan *et al.*, "Translational Regulation of the Mitochondrial Genome Following Redistribution of Mitochondrial MicroRNA in the Diabetic Heart," pp. 785–802, 2015.
- [249] H. Tan, H. Li, and P. Jin, "Neuroscience Letters RNA-mediated pathogenesis in fragile X-associated disorders," vol. 466, pp. 103–108, 2009.
- [250] S. Zongaro *et al.*, "The 3' UTR of FMR1 mRNA is a target of miR-101 , miR-129-5p and miR-221 : implications for the molecular pathology of FXTAS at the synapse," vol. 22, no. 10, pp. 1971–1982, 2018.
- [251] L. Sripada, D. Tomar, and R. Singh, "Author ' s personal copy Mitochondrion Mitochondria : One of the destinations of miRNAs."
- [252] B. Wang *et al.*, "FMRP-Mediated Axonal Delivery of miR-181d Regulates Axon Elongation by Locally Targeting Article FMRP-Mediated Axonal Delivery of miR-181d Regulates Axon Elongation by Locally Targeting Map1b and Calm1," *CellReports*, vol. 13, no. 12, pp. 2794–2807, 2015.
- [253] S. Mansouri, Q. Pan, B. J. Blencowe, J. M. Claycomb, and L. Frappier, "Epstein-Barr Virus EBNA1 Protein Regulates Viral Latency through Effects on let-7 MicroRNA and Dicer," vol. 88, no. 19, pp. 11166–11177, 2014.
- [254] S. Fan *et al.*, "Mitochondrial miRNA determines chemoresistance by reprogramming metabolism and regulating mitochondrial transcription," *Cancer Res.*, vol. 79, no. 6, pp. 1069–1084, 2019.
- [255] X. Liang, H. Sun, J. G. Nichols, and S. T. Crooke, "RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus," *Mol. Ther.*, vol. 25, no. 9, pp. 2075–2092, 2017.